Cargando...
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
The oral multikinase inhibitor sunitinib malate was approved by the U.S. Food and Drug Administration in January 2006 for use in patients with advanced renal cell carcinoma (RCC). Since then, it has been approved globally for this indication and for patients with imatinib‐resistant or ‐intolerant ga...
Guardado en:
| Publicado en: | Oncologist |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley-Blackwell
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313263/ https://ncbi.nlm.nih.gov/pubmed/27807302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0197 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|